Search

Your search keyword '"Chandele A"' showing total 247 results

Search Constraints

Start Over You searched for: Author "Chandele A" Remove constraint Author: "Chandele A"
247 results on '"Chandele A"'

Search Results

202. Pathogenicity of Different Isolates of Entomopathogenic Fungus, Nomuraea rileyi(Farlow) Samson Against Tobacco Caterpillar, Spodoptera litura(Fabricius)

203. Chikungunya-specific IgG and neutralizing antibody responses in natural infection of Chikungunya virus in children from India.

204. Inter-identity amnesia for neutral episodic self-referential and autobiographical memory in Dissociative Identity Disorder: An assessment of recall and recognition.

205. Regional Variation of the CD4 and CD8 T Cell Epitopes Conserved in Circulating Dengue Viruses and Shared with Potential Vaccine Candidates.

206. Analysis Of Human Papilloma Virus In Oral Squamous Cell Carcinoma Using P16.

207. Functional and transcriptional heterogeneity within the massively expanding HLADR+CD38+ CD8 T cell population in acute febrile dengue patients.

208. Prediction of human protein interactome of dengue virus non-structural protein 5 (NS5) and its downstream immunological implications.

209. Structural Profiles of SARS-CoV-2 Variants in India.

210. A multicentric study on dermoscopic patterns and clinical–dermoscopic–histological correlates of basal cell carcinoma in Indian skin.

212. Inflammation Directs Memory Precursor and Short-Lived Effector CD8+ T Cell Fates via the Graded Expression of T-bet Transcription Factor

213. Molecular surveillance of Dengue Virus (DENV) and its co-infection with Chikungunya Virus (CHIKV) among febrile patients: A comparative study from South Delhi, India.

214. Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India.

215. Emergence of new genotypes and lineages of dengue viruses during the 2012–15 epidemics in southern India.

216. Isolation and molecular characterization of dengue virus clinical isolates from pediatric patients in New Delhi.

217. Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses.

218. Clinical, Serological, and Virological Analysis of 572 Chikungunya Patients From 2010 to 2013 in India.

219. Enhancing the sensitivity of Dengue virus serotype detection by RT-PCR among infected children in India.

220. Plant dehydroascorbate reductase moonlights as membrane integrated ion channel.

221. Short communication: Virological and B cell profiles of chikungunya and Dengue virus co-infections in Delhi during 2017–2019.

222. Transcriptional Repressor Blimp-1 Promotes CD8+ T Cell Terminal Differentiation and Represses the Acquisition of Central Memory T Cell Properties

223. High-mobility group box 1 protein promotes dengue virus replication by interacting with untranslated regions of viral genome.

224. Severe disease during both primary and secondary dengue virus infections in pediatric populations.

225. Viremia and clinical manifestations in acute febrile patients of Chikungunya infection during the 2016 CHIKV outbreak in Delhi, India.

226. Neutralizing antibodies from prior exposure to dengue virus negatively correlate with viremia on re-infection.

227. Light chain of a public SARS-CoV-2 class-3 antibody modulates neutralization against Omicron.

228. Oxidized LDL receptors: a recent update.

229. Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response.

230. Profiles of host immune impairment in Plasmodium and SARS-CoV-2 infections.

231. Correction: Current status of therapeutic monoclonal antibodies against SARS-CoV-2.

232. Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response.

233. Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody.

234. Broadly Neutralizing Antibodies to SARS-CoV-2 Provide Novel Insights Into the Neutralization of Variants and Other Human Coronaviruses.

235. Contrasting behavior between the three human monocyte subsets in dengue pathophysiology.

236. Optimization of Flow-Cytometry Based Assay for Measuring Neutralizing Antibody Responses against Each of the Four Dengue Virus Serotypes.

237. Immunophenotyping and Transcriptional Profiling of Human Plasmablasts in Dengue.

238. Current status of therapeutic monoclonal antibodies against SARS-CoV-2.

239. Epidemiology and molecular characterization of chikungunya virus from human cases in North India, 2016.

240. Dengue Virus Non-Structural Protein 5 as a Versatile, Multi-Functional Effector in Host-Pathogen Interactions.

241. Antibody response patterns in chikungunya febrile phase predict protection versus progression to chronic arthritis.

242. Analysis of dengue specific memory B cells, neutralizing antibodies and binding antibodies in healthy adults from India.

243. High yield expression and purification of Chikungunya virus E2 recombinant protein and its evaluation for serodiagnosis.

244. A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents.

245. Identification of novel Mycobacterium tuberculosis CD4 T-cell antigens via high throughput proteome screening.

246. Differential expression of Ly6C and T-bet distinguish effector and memory Th1 CD4(+) cell properties during viral infection.

247. ROS-triggered caspase 2 activation and feedback amplification loop in beta-carotene-induced apoptosis.

Catalog

Books, media, physical & digital resources